Beranda › Liposarcoma
Uji klinis Liposarcoma yang merekrut di AS
17 studi untuk Liposarcoma merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX10 studi
- Boston, MA7 studi
- Queens, NY5 studi
- New York City, NY5 studi
- Chicago, IL5 studi
- St. Louis, MO5 studi
- Edison, NJ4 studi
- Atlanta, GA4 studi
- Seattle, WA3 studi
- Greenburgh, NY3 studi
- New Rochelle, NY3 studi
- Nashville, TN3 studi
- Tampa, FL3 studi
- Miami, FL3 studi
- San Diego, CA3 studi
- Louisville, KY3 studi
- Rochester, MN3 studi
- Columbus, OH3 studi
- Gainesville, FL3 studi
- Aurora, CO3 studi
- Phoenix, AZ3 studi
- Pittsburgh, PA3 studi
- Richmond, VA3 studi
Berdasarkan negara bagian
- Arizona3 studi
- California6 studi
- Colorado3 studi
- Connecticut3 studi
- Florida4 studi
- Georgia4 studi
- Illinois5 studi
- Kentucky3 studi
- Massachusetts7 studi
- Michigan4 studi
- Minnesota3 studi
- Missouri5 studi
- New Jersey5 studi
- New York6 studi
- Ohio6 studi
- Pennsylvania4 studi
- Tennessee4 studi
- Texas11 studi
- Virginia5 studi
- Washington3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06422806Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06498648A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06881992A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06025747A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06843967Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04031677Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06578624Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05711615Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06975293Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT04715191NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06239272A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07089992Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT07377747A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT06789172Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Menerima pesertaFase 1
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 3 Nov 2025 · NCT06198296Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.